Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P49918

UPID:
CDN1C_HUMAN

ALTERNATIVE NAMES:
Cyclin-dependent kinase inhibitor p57; p57Kip2

ALTERNATIVE UPACC:
P49918

BACKGROUND:
The protein Cyclin-dependent kinase inhibitor 1C, alternatively named p57Kip2, acts as a potent inhibitor of cell cycle regulators, ensuring proper cell growth and division control. Its ability to negatively regulate cell proliferation underscores its importance in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given its association with diseases such as Beckwith-Wiedemann syndrome and adrenal hypoplasia congenita, Cyclin-dependent kinase inhibitor 1C represents a promising avenue for drug discovery. Exploring its functions further could lead to novel treatments for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.